Skip to content
Calculator
Evidence: MediumPeptideResearch ChemicalEndogenous neuropeptideResearch use onlyMigraine trigger

PACAP

The neuropeptide that sets off migraine when infused, studied by provocation

PACAP, pituitary adenylate cyclase-activating polypeptide, is a natural neuropeptide. When researchers infuse it into people with migraine, many develop a migraine-like attack, and blocking CGRP does not stop it. That makes PACAP a separate route into migraine; an antibody that blocks it is in trials and is listed under References. PACAP itself is not a treatment.

Used in human trials: 10 pmol/kg/min (PACAP38), Single 20-minute infusion, Infusion (Study: provocation in healthy volunteers) Details ↓

Overview

What is it?

Migraine research has a useful tool: give a substance by infusion and see whether it provokes an attack in people who get migraines. CGRP passed that test, and drugs that block CGRP are now standard treatments. PACAP passes it too. In a randomised crossover study, PACAP-27 provoked migraine-like attacks in 55% of patients against 10% after placebo, and PACAP-38 does the same, making it one of the few molecules shown to trigger attacks in a controlled setting.

The key question was whether PACAP acts through CGRP. In a 2025 trial, 38 migraine patients received the CGRP antibody eptinezumab or placebo before a PACAP-38 infusion; attacks followed in 53% and 63%, a difference that was not significant. Blocking CGRP did not block PACAP, so the two can be targeted separately. Early sumatriptan did reduce PACAP-38-induced attacks, from 42% to 15%, and constricted the dilated temporal artery. Glibenclamide, a potassium-channel blocker, did not change PACAP-38 headache in healthy volunteers.

The provocation studies also showed where PACAP acts. Infused into healthy volunteers at 10 pmol/kg/min for 20 minutes, PACAP38 widened the middle meningeal artery, which runs in the coverings of the brain, by up to 23% for more than five hours, while the main artery inside the brain stayed the same width. In rats, that delayed widening depended on mast cells and histamine. In migraine patients it also produced premonitory symptoms in about half, something CGRP did not do.

In cluster headache, PACAP-38 and VIP infusions provoke attacks in up to half of patients in an active phase, and those attacks came without changes in blood CGRP or mast-cell markers.

PACAP itself is used only as a research agent in these provocation studies; it is not sold or prescribed as a treatment. These findings led to drugs that block PACAP, among them the antibody Lu AG09222, whose phase 2 trial is listed under References.

PACAP turns up outside headache research too. In adults exposed to trauma, a subgroup of mostly women with blood PACAP38 more than twice as high as others had more intrusive and hypervigilant PTSD symptoms and weaker fear extinction, and in rodent stroke models PACAP38 protected neurons. Blood levels, though, are not a diagnostic test: a 2026 systematic review found the migraine studies inconsistent and all at high risk of bias.

>5 h
Meningeal artery dilation after one infusion
healthy volunteers, PACAP38 · PMID 22174350
48%
Migraine patients with premonitory symptoms
after PACAP38; none after CGRP · PMID 27842045
2×
Blood PACAP38 in a PTSD subgroup
about 14% of a trauma-exposed sample · PMID 39892206
Science

Mechanism of Action

PACAP exists as a 38-amino-acid form (PACAP38) and a shorter 27-amino-acid form. It acts on the PAC1 receptor and on two receptors it shares with VIP.

🧠

Migraine provocation

Infusions trigger migraine-like attacks in people with migraine and headache in healthy volunteers.

🩸

Vessel dilation

It widens arteries outside the brain for hours, partly through mast cells and histamine in animal work.

😨

Stress and fear

Blood levels track fear-related arousal and a subtype of PTSD in human studies.

🛡️

Neuroprotection

In rodent stroke models it protected neurons directly and through neurotrophins.

Evidence

Published Research

Studies of PACAP, from their PubMed abstracts.

Human2025

PACAP-38 attacks with CGRP blocked

In 38 migraine patients, PACAP-38-induced migraine attacks occurred in 10 of 19 after eptinezumab and 12 of 19 after placebo (P = 0.74), and headache intensity did not differ.

PMID: 40229719
Human2021

Sumatriptan and PACAP-38 migraine

Of 26 patients, 15% developed a PACAP-38-induced attack on sumatriptan versus 42% on placebo (p = 0.016); sumatriptan constricted the PACAP-38-dilated superficial temporal artery.

PMID: 33567890
Human2020

PACAP-27 provocation

PACAP-27 provoked migraine-like attacks in 11 of 20 patients (55%) versus 2 after placebo (10%; p = 0.022), with greater headache intensity and duration.

PMID: 31299857
Human2022

Glibenclamide and PACAP-38 headache

In 20 healthy volunteers, PACAP-38-induced headache occurred in 95% after glibenclamide and 90% after placebo (P = 0.698), with no difference in artery diameters or blood flow.

PMID: 35301859
Human2022

Provoked cluster headache attacks

In 44 cluster headache patients given PACAP-38 (10 pmol/kg/min) or VIP for 20 minutes, provoked attacks were not accompanied by changes in plasma CGRP, tryptase or histamine.

PMID: 34822741
Human2012

Meningeal artery dilation in volunteers

In healthy volunteers given a 20-minute infusion of 10 pmol/kg/min PACAP38, MRI showed the middle meningeal artery outside the brain dilated by 16 to 23% for more than five hours, while the middle cerebral artery inside the brain did not change. Sumatriptan contracted the meningeal artery as the headache eased.

PMID: 22174350
Human2019

PACAP-27 and cerebral blood vessels

In healthy volunteers, PACAP-27 caused headache in 9 of 12 against 1 after placebo, dilated arteries outside the brain for more than five hours and slightly narrowed the middle cerebral artery. PACAP-38 dilated the meningeal artery more than PACAP-27 did.

PMID: 31449829
Human2016

Premonitory symptoms after infusion

In migraine patients, PACAP38 infusion brought on premonitory symptoms in 48%, whereas CGRP did not; those who went on to an attack were no more likely to report them.

PMID: 27842045
Human2023

Blocking PACAP's effects in healthy volunteers

In a randomised proof-of-mechanism study, the PACAP antibody Lu AG09222 blocked PACAP38-induced widening of head blood vessels, the rise in heart rate and the mild headache that followed the infusion.

PMID: 37231350
Human2015

Blood levels between migraine attacks

Between attacks, plasma PACAP was lower in episodic and chronic migraine than in the matching forms of tension-type headache, and in chronic migraine it fell further the longer the disease had lasted.

PMID: 26296898
Human2025

PTSD subgroup with high PACAP

In adults with trauma exposure, a subgroup of about 14%, mostly women, had blood PACAP38 more than twice as high as the others, along with intrusive and hypervigilant PTSD symptoms and weaker retention of fear extinction.

PMID: 39892206
Human2025

PACAP and fear arousal

In adults with posttraumatic stress symptoms, higher circulating PACAP went with stronger startle during fear learning, higher heart rate and lower heart-rate variability during extinction, with no difference by sex. The authors say causation is not established.

PMID: 40657352
Review2026

Blood PACAP as a migraine marker

A 2026 systematic review found studies of plasma or serum PACAP-38 in migraine inconsistent, rarely comparing the same person during and between attacks, and all at high risk of bias. Blood PACAP is not a usable migraine test.

PMID: 42578875
Animal2014

Mast cells and delayed artery dilation (rats)

In rats, PACAP-38 infusion caused a delayed, sustained widening of the middle meningeal artery that was blunted when mast cells were depleted or histamine was blocked, while VIP lowered blood pressure without the same dilation.

PMID: 24563332
Animal2012

Neuroprotection in stroke models

In cell models of oxygen and glucose deprivation and in rats with blocked cerebral arteries, PACAP38 protected neurons through its own receptors and indirectly by releasing neurotrophins and damping growth-inhibiting signals.

PMID: 22678884
Dosing

Dosing Data

PACAP is not a medicine. It is given only in research, as a short infusion to provoke headache under supervision.

This is a research dose used to cause headache and migraine-like attacks on purpose. It is not a treatment. See a doctor first; PACAP-based migraine drugs are antibodies that block PACAP, not PACAP itself.
ProtocolDoseFrequencyDurationRoute
Study: provocation in healthy volunteers Human studyPMID 2217435010 pmol/kg/min (PACAP38)Single 20-minute infusionSingle sessionInfusion

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Infusion rate
Research infusions ran at 10 pmol/kg/min for 20 minutes to provoke headache. There is no treatment dose.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes PACAP is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: infusion). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store PACAP, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long PACAP stays intact once mixed.

How it is taken

As it was given in human studies: Infusion (Single 20-minute infusion; Study: provocation in healthy volunteers).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Study: provocation in healthy volunteers: Single session.

When effects appear: unknown; no source on this page gives a time to effect for PACAP. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Headache and migraine-like attacks in people with migraine; Dilation of cranial arteries. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping PACAP. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the infusion studies above, where provoking these effects was the point”).

Interactions

  • sumatriptan: early sumatriptan reduced PACAP-38-induced migraine attacks (15% vs 42%) and constricted the dilated temporal artery
  • eptinezumab (CGRP antibody): did not reduce PACAP-38-induced migraine attacks (53% vs 63%, P = 0.74)
  • glibenclamide: did not change PACAP-38-induced headache or haemodynamic changes in healthy volunteers

Every peptide's record, with its source: the interaction matrix.

Source: human study, PMID 33567890; human study, PMID 40229719; human study, PMID 35301859.

Checking what you bought

Unknown: no published independent test of PACAP products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against PACAP's expected mass, 4,534.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Research Chemical (Not a medicine: PACAP itself is used only as a research provocation agent, and openFDA's Drugs@FDA index returns no record for it (searched October 3, 2026)). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the infusion studies above, where provoking these effects was the point.

● Headache and migraine-like attacks in people with migraine
● Dilation of cranial arteries

Contraindications & Cautions

There is no label; PACAP is a research agent.

● Not approved for any use
Questions

Frequently Asked Questions

?What is PACAP?

Pituitary adenylate cyclase-activating polypeptide, a natural neuropeptide that exists as PACAP-38 and a shorter PACAP-27. In research it is infused to provoke migraine and cluster headache attacks.

?Does PACAP cause migraine?

Infusing it provokes migraine-like attacks in many people with migraine, which is evidence it takes part in migraine. Whether it causes everyday attacks is still being studied.

?Is PACAP the same pathway as CGRP?

No. Blocking CGRP with eptinezumab did not stop PACAP-38 from triggering attacks, which is why PACAP-blocking drugs are being developed as a separate option.

?Is there a PACAP drug for migraine?

Not an approved one: the antibody Lu AG09222, which blocks PACAP, is in trials and is listed under References.

?Can a blood test for PACAP diagnose migraine?

No. A 2026 systematic review found blood PACAP studies in migraine inconsistent and all at high risk of bias.

?Is PACAP linked to PTSD?

In some studies. A subgroup of trauma-exposed adults, mostly women, had blood PACAP38 more than twice as high as others, along with intrusive and hypervigilant symptoms and weaker fear extinction. That is an association, not proof of cause.

Bibliography

References

  1. [other] PubChem CID 91935803, PACAP-38: formula C203H331N63O53S, molecular weight 4534. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/91935803
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for PACAP. Read October 3, 2026.
  3. [clinical-trial] Al-Karagholi MA, et al. "PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial." J Headache Pain, 2025;26(1):79. PMID: 40229719.
  4. [clinical-trial] Wienholtz NKF, et al. "Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial." Cephalalgia, 2021;41(6):731-748. PMID: 33567890.
  5. [clinical-trial] Ghanizada H, et al. "PACAP27 induces migraine-like attacks in migraine patients." Cephalalgia, 2020;40(1):57-67. PMID: 31299857.
  6. [clinical-trial] Ashina M, et al. "A Monoclonal Antibody to PACAP for Migraine Prevention." N Engl J Med, 2024;391(9):800-809. PMID: 39231342.
  7. [clinical-trial] Kokoti L, et al. "Effect of K(ATP) channel blocker glibenclamide on PACAP38-induced headache and hemodynamic." Cephalalgia, 2022;42(9):846-858. PMID: 35301859.
  8. [pubmed] Pellesi L, et al. "PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation." Cephalalgia, 2022;42(8):687-695. PMID: 34822741.
  9. [pubmed] Amin FM, et al. "Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers." Cephalalgia, 2012;32(2):140-9. PMID: 22174350.
  10. [pubmed] Ghanizada H, et al. "Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study." Peptides, 2019;121:170134. PMID: 31449829.
  11. [pubmed] Guo S, et al. "Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine." Pain, 2016;157(12):2773-2781. PMID: 27842045.
  12. [pubmed] Rasmussen NB, et al. "The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study." J Headache Pain, 2023;24(1):60. PMID: 37231350.
  13. [pubmed] Han X, et al. "Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache." Clin Chim Acta, 2015;450:151-4. PMID: 26296898.
  14. [pubmed] Jørgensen PL, et al. "Blood levels of PACAP in migraine: A systematic review." Cephalalgia, 2026;46(8):3331024261468031. PMID: 42578875.
  15. [pubmed] Adams SW, et al. "PACAP associated with precise PTSD and fear extinction response in women." Psychoneuroendocrinology, 2025;173:107375. PMID: 39892206.
  16. [pubmed] Seligowski AV, et al. "Associations between PACAP levels and psychophysiological indicators of fear and arousal in adults with posttraumatic stress symptoms." J Mood Anxiety Disord, 2025;11:100128. PMID: 40657352.
  17. [pubmed] Bhatt DK, et al. "PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells." Cephalalgia, 2014;34(11):877-86. PMID: 24563332.
  18. [pubmed] Lazarovici P, et al. "Multimodal neuroprotection induced by PACAP38 in oxygen-glucose deprivation and middle cerebral artery occlusion stroke models." J Mol Neurosci, 2012;48(3):526-40. PMID: 22678884.

Sources & Citations

Studies were read from their PubMed abstracts. Animal findings are labelled as such. Read October 16, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-19